1. A method for treating obesity in humans comprising the step of administering to a human in need of such treatment a therapeutically
effective amount of a pharmaceutical composition comprising: (i) (1S,2S,3S,4R,5S)-5-[-4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol;
(ii) a pharmaceutically acceptable excipient, diluent, or carrier and (iii) sitagliptin; or a pharmaceutically acceptable
salt thereof.